Final analysis of the phase 3 BRIGHT-2 trial (305 patients with HR-positive, ERBB2-negative advanced breast cancer after endocrine progression): bireociclib plus fulvestrant vs placebo plus fulvestrant improved median PFS (14.7 vs 7.3 months; HR 0.54).
RCTn = 305
Wang et al. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial